Last reviewed · How we verify

NCT04284904: GVHD

Role of aGVHD Biomarkers on aGVHD Risks

Status unknown Last updated 26 February 2020
What this trial tests

trial testing aGVHD biomarker in GVHD,Acute in 500 participants. Status unknown.

Timeline
1 July 2018
Primary endpoint
31 December 2023
31 December 2023

Quick facts

Lead sponsorChinese PLA General Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment500
Start date1 July 2018
Primary completion31 December 2023
Estimated completion31 December 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

Under 65, any sex, with GVHD,Acute or Biomarker. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To establish risk rating criteria of biological protein marker, determine the role and consistency of aGVHD biomarkers in aGVHD diagnosis and aGVHD prognosis, and evaluate the the impact on non-relapse mortality and relapse and disease free survival, the multicenter study on aGVHD biomarkers detection in the patients underwent allogeneic hematopoietic stem cell transplantation was performed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for GVHD,Acute

Currently open trials in the same condition.

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04284904.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing